wenxi tan

Dr. wenxi tan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
SXShengnan Xie
Shengnan Xie
LLLi Li
Li Li
BZBaihe Zhan
Baihe Zhan
XSXue Shen
Xue Shen
XDXuming Deng
Xuming Deng
TFTianqi Fang
Tianqi Fang
The emergence of the plasmid-mediated colistin resistance gene mcr-1 has resulted in the loss of available treatments for certain severe infections. Here we identified a potential inhibitor of MCR-1 for the treatment of infections caused by MCR-1-positive drug-resistant bacteria, especially MCR-1-positive carbapenem-resistant Enterobacteriaceae (CRE). A checkerboard minimum inhibitory concentration (MIC) test, a killing curve test, a growth curve test, bacterial live/dead assays, scanning electron microscope (SEM) analysis, cytotoxicity tests, molecular dynamics simulation analysis, and animal studies were used to confirm the in vivo/in vitro synergistic effects of pogostone and colistin. The results showed that pogostone could restore the bactericidal activity of colistin against all tested MCR-1-positive bacterial strains or MCR-1 mutant–positive bacterial strains (FIC < 0.5). Pogostone does not inhibit the expression of MCR-1. Rather, it inhibits the binding of MCR-1 to substrates by binding to amino acids in the active region of MCR-1, thus inhibiting the biological activity of MCR-1 and its mutants (such as MCR-3). An in vivo mouse systemic infection model, pogostone in combination with colistin resulted in 80.0% (the survival rates after monotherapy with colistin or pogostone alone were 33.3% and 40.0%) survival at 72 h after infection of MCR-1-positve Escherichia coli (E. coli) ZJ487 (blaNDM-1-carrying), and pogostone in combination with colistin led to one or more order of magnitude decreases in the bacterial burdens in the liver, spleen and kidney compared with pogostone or colistin alone. Our results confirm that pogostone is a potential inhibitor of MCR-1 for use in combination with polymyxin for the treatment of severe infections caused by MCR-1-positive Enterobacteriaceae.


24 September 2024 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
LWLanqiao Wang
Lanqiao Wang
JFJuan Fang
Juan Fang
HWHeng Wang
Heng Wang
BZBaoyu Zhang
Baoyu Zhang
NWNan Wang
Nan Wang
QZQiaoling Zhang
Qiaoling Zhang

28 February 2023 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
LDLu Ding
Lu Ding
WTwenxi tan
wenxi tan
YWYunfei Wei
Yunfei Wei
HYHao Yu
Hao Yu
LZLilei Zhao
Lilei Zhao
HFHaihua Feng
Haihua Feng

1 January 2023 in Open Life Sciences
Verified
Journal Article
Open access
PDF file
BZBenzheng Zhao
Benzheng Zhao
WZWeixin Zhao
Weixin Zhao
YXYang Xia
Yang Xia
JLJian Liu
Jian Liu
YWYuan Wang
Yuan Wang
SZShuhua Zhao
Shuhua Zhao
Small cell lung cancer (SCLC) rarely metastasizes to the ovary, and is difficult to diagnose given its overlapping clinical features and histological characteristics with primary ovarian cancer. Since therapies for SCLC and primary ovarian cancer differ, it is important to determine the original site of ovarian lesions. This report describes the differential diagnosis of metastatic from primary ovarian cancer. A 46-year-old Chinese woman with a history of SCLC, confirmed by transbronchial lung biopsy in August 2018, presented with abdominal distension in December 2018. Ultrasound examination and whole abdomen computed tomography showed one mass in each ovary. A provisional diagnosis of ovarian tumor was given. A palliative total abdominal hysterectomy and bilateral salpingo-oophorectomy was performed; and three postoperative courses of chemotherapies. The patient died from multiple organ failure in May 2019. Metastatic ovarian cancer from SCLC was determined based on characteristic histological and immunohistochemical staining.